Monopar TherapeuticsMNPR +9.14%35 Quick Ratio is 56.04 as of Mar. 2026, which is 210% above its 10-year median of 18.10. GuruFocus rates MNPR with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 1,417 Biotechnology companies, Monopar Therapeutics ranks better than 98.73% on this metric.
Monopar Therapeutics has a quick ratio of 56.04. It generally indicates good short-term financial strength.
The historical rank and industry rank for Monopar Therapeutics's Quick Ratio or its related term are showing as below:
MNPR'
s Quick Ratio Range Over the Past 10 Years
Min: 4.08 Med: 18.1 Max: 56.09
Current: 56.04
During the past 10 years, Monopar Therapeutics's highest Quick Ratio was 56.09. The lowest was 4.08. And the median was 18.10.
MNPR's Quick Ratio is ranked better than 98.73% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs MNPR: 56.04
Monopar Therapeutics (NAS:MNPR) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Monopar Therapeutics Quick Ratio Related Terms
Monopar Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Monopar Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Monopar Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monopar Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Monopar Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Monopar Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Monopar Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monopar Therapeutics (MNPR) has a Quick Ratio of 56.04 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Monopar Therapeutics and its competitors. This is 210% above median its historical median of 18.10. Over the past decade, Monopar Therapeutics' Quick Ratio has ranged from 4.08 to 56.09. According to the industry distribution chart, Monopar Therapeutics ranks #18 out of 1417 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Monopar Therapeutics' Quick Ratio too high?
Monopar Therapeutics' current Quick Ratio of 56.04 is 210% above median its 10-year median of 18.10. Over the past 10 years, this metric has ranged from a low of 4.08 to a high of 56.09. The Biotechnology industry median Quick Ratio is 3.60. Monopar Therapeutics' value of 56.04 is 1456.7% above this industry median. Based on the distribution chart, Monopar Therapeutics ranks #18 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Monopar Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Monopar Therapeutics' Quick Ratio compare to IPSC and ADCT?
According to the Biotechnology industry distribution chart, Monopar Therapeutics ranks #18 out of 1417 companies for Quick Ratio. This places Monopar Therapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Monopar Therapeutics' value of 56.04 is 1456.7% above this benchmark. Historically, Monopar Therapeutics' own Quick Ratio has ranged from 4.08 to 56.09 over the past decade. While the company's 10-year median is 18.10 vs. the industry median of 3.60, Monopar Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Monopar Therapeutics's current Quick Ratio of 56.04 is 1456.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Monopar Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monopar Therapeutics's current Quick Ratio is 56.04, which is 210% above median its own 10-year median of 18.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monopar Therapeutics stock overvalued right now?
Monopar Therapeutics (MNPR) has a current Quick Ratio of 56.04. The current Quick Ratio is 56.04, which is 210% above median its 10-year median of 18.10 and 1456.7% above the Biotechnology industry median of 3.60. Monopar Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Monopar Therapeutics (MNPR), the current Quick Ratio is 56.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
35GF Score
Get the complete analysis for MNPR
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNPR has been successfully added to your 
